The coxibs are a subclass of nonsteroidal antiinflammatory drugs(NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2).1Their development was based on the hypothesis that COX-2 wasthe source of prostaglandins E2 and I2, which mediate inflammation,and that cyclooxygenase-1 (COX-1) was the source of the sameprostaglandins in gastric epithelium, where they afford cytoprotection.Three coxibs — celecoxib, rofecoxib, and valdecoxib —have been approved for use by the Food and Drug Administration(FDA); a fourth, etoricoxib, has been approved by the Europeanregulatory authority, and it and a fifth, lumiracoxib, are currentlyunder consideration for FDA approval.
Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D.
(2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford)
0: ken159v1-ken159
[Abstract][Full Text]
Clark, P., Rowland, S. E., Denis, D., Mathieu, M.-C., Stocco, R., Poirier, H., Burch, J., Han, Y., Audoly, L., Therien, A. G., Xu, D.
(2008). MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis. J. Pharmacol. Exp. Ther.
325: 425-434
[Abstract][Full Text]
Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Powell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., Hwa, J.
(2008). Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition. Circ. Res.
102: 986-993
[Abstract][Full Text]
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., Pater, J. L., Goss, P. E., Lance, P., Obara, S., Chew, E. Y., Kim, J., Arndt, G., Hawk, E., for the Cross Trial Safety Assessment Group,
(2008). Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation
117: 2104-2113
[Abstract][Full Text]
Taketa, K., Matsumura, T., Yano, M., Ishii, N., Senokuchi, T., Motoshima, H., Murata, Y., Kim-Mitsuyama, S., Kawada, T., Itabe, H., Takeya, M., Nishikawa, T., Tsuruzoe, K., Araki, E.
(2008). Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages. J. Biol. Chem.
283: 9852-9862
[Abstract][Full Text]
Subbaramaiah, K., Hudis, C., Chang, S.-H., Hla, T., Dannenberg, A. J.
(2008). EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE. J. Biol. Chem.
283: 3433-3444
[Abstract][Full Text]
Kardosh, A., Golden, E. B., Pyrko, P., Uddin, J., Hofman, F. M., Chen, T. C., Louie, S. G., Petasis, N. A., Schonthal, A. H.
(2008). Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib. Cancer Res.
68: 843-851
[Abstract][Full Text]
Frolov, R. V., Berim, I. G., Singh, S.
(2008). Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT. J. Biol. Chem.
283: 1518-1524
[Abstract][Full Text]
Joshi, G. P., Gertler, R., Fricker, R.
(2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg.
105: 1793-1804
[Abstract][Full Text]
Letts, G., Loscalzo, J.
(2007). Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors. J. Am. Soc. Nephrol.
18: 2863-2869
[Abstract][Full Text]
Frye, R. L.
(2007). Update in Cardiology. ANN INTERN MED
147: 180-186
[Full Text]
Mosca, M., Polentarutti, N., Mangano, G., Apicella, C., Doni, A., Mancini, F., De Bortoli, M., Coletta, I., Polenzani, L., Santoni, G., Sironi, M., Vecchi, A., Mantovani, A.
(2007). Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. J. Leukoc. Biol.
82: 320-326
[Abstract][Full Text]
Klein, T., Eltze, M., Grebe, T., Hatzelmann, A., Komhoff, M.
(2007). Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res
75: 390-397
[Abstract][Full Text]
Habib, A., Shamseddeen, I., Nasrallah, M. S., Antoun, T. A., Nemer, G., Bertoglio, J., Badreddine, R., Badr, K. F.
(2007). Modulation of COX-2 expression by statins in human monocytic cells. FASEB J.
21: 1665-1674
[Abstract][Full Text]
Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., Louie, S. G., Chen, T. C., Schonthal, A. H.
(2007). Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics
6: 1262-1275
[Abstract][Full Text]
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A.
(2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation
115: 1634-1642
[Full Text]
Gross, S., Tilly, P., Hentsch, D., Vonesch, J.-L., Fabre, J.-E.
(2007). Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J. Exp. Med.
204: 311-320
[Abstract][Full Text]
Yu, Y., Fan, J., Hui, Y., Rouzer, C. A., Marnett, L. J., Klein-Szanto, A. J., FitzGerald, G. A., Funk, C. D.
(2007). Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality. J. Biol. Chem.
282: 1498-1506
[Abstract][Full Text]
Gitlin, J. M., Trivedi, D. B., Langenbach, R., Loftin, C. D.
(2007). Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res
73: 227-236
[Abstract][Full Text]
Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., O'Donnell, V. B.
(2006). Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood
108: 4059-4062
[Abstract][Full Text]
Stitham, J., Gleim, S. R., Douville, K., Arehart, E., Hwa, J.
(2006). Versatility and Differential Roles of Cysteine Residues in Human Prostacyclin Receptor Structure and Function. J. Biol. Chem.
281: 37227-37236
[Abstract][Full Text]
Jia, Z., Zhang, A., Zhang, H., Dong, Z., Yang, T.
(2006). Deletion of Microsomal Prostaglandin E Synthase-1 Increases Sensitivity to Salt Loading and Angiotensin II Infusion. Circ. Res.
99: 1243-1251
[Abstract][Full Text]
Massaro, M., Habib, A., Lubrano, L., Turco, S. D., Lazzerini, G., Bourcier, T., Weksler, B. B., De Caterina, R.
(2006). The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC{varepsilon} inhibition. Proc. Natl. Acad. Sci. USA
103: 15184-15189
[Abstract][Full Text]
Yang, L., Huang, Y., Porta, R., Yanagisawa, K., Gonzalez, A., Segi, E., Johnson, D. H., Narumiya, S., Carbone, D. P.
(2006). Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism. Cancer Res.
66: 9665-9672
[Abstract][Full Text]
Schmelzer, K. R., Inceoglu, B., Kubala, L., Kim, I.-H., Jinks, S. L., Eiserich, J. P., Hammock, B. D.
(2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA
103: 13646-13651
[Abstract][Full Text]
Wang, H.-W., Hsueh, C.-T., Lin, C.-F. J., Chou, T.-Y., Hsu, W.-H., Wang, L.-S., Wu, Y.-C.
(2006). Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non-Small-Cell Lung Cancer. Ann. Surg. Oncol.
13: 1224-1234
[Abstract][Full Text]
Szerafin, T., Erdei, N., Fulop, T., Pasztor, E. T., Edes, I., Koller, A., Bagi, Z.
(2006). Increased Cyclooxygenase-2 Expression and Prostaglandin-Mediated Dilation in Coronary Arterioles of Patients With Diabetes Mellitus. Circ. Res.
99: e12-317
[Abstract][Full Text]
Lovgren, A. K., Jania, L. A., Hartney, J. M., Parsons, K. K., Audoly, L. P., FitzGerald, G. A., Tilley, S. L., Koller, B. H.
(2006). COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol.
291: L144-L156
[Abstract][Full Text]
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O'Neill, G., Fagan, S. C., Cudkowicz, M. E.
(2006). Neuroprotective agents for clinical trials in ALS: A systematic assessment.. Neurology
67: 20-27
[Abstract][Full Text]
Komhoff, M., Klaus, G., Nazarowa, S., Reinalter, S. C., Seyberth, H. W.
(2006). Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss. Nephrol Dial Transplant
21: 1833-1837
[Abstract][Full Text]
Roca-Ferrer, J, Pujols, L, Gartner, S, Moreno, A, Pumarola, F, Mullol, J, Cobos, N, Picado, C
(2006). Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax
61: 592-596
[Abstract][Full Text]
Andersohn, F., Schade, R., Suissa, S., Garbe, E.
(2006). Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke: A Nested Case-Control Study. Stroke
37: 1725-1730
[Abstract][Full Text]
Carothers, A. M., Moran, A. E., Cho, N. L., Redston, M., Bertagnolli, M. M.
(2006). Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.. Cancer Res.
66: 6432-6438
[Abstract][Full Text]
Grosch, S., Maier, T. J., Schiffmann, S., Geisslinger, G.
(2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.. JNCI J Natl Cancer Inst
98: 736-747
[Abstract][Full Text]
Authors/Task Force Members, , Fox, K., Garcia, M. A. A., Ardissino, D., Buszman, P., Camici, P. G., Crea, F., Daly, C., De Backer, G., Hjemdahl, P., Lopez-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L, Andreotti, F., Becher, H., Dietz, R., Fraser, A., Gray, H., Antolin, R. A. H., Huber, K., Kremastinos, D. T., Maseri, A., Nesser, H.-J., Pasierski, T., Sigwart, U., Tubaro, M., Weis, M.
(2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J
27: 1341-1381
[Full Text]
Andersohn, F., Suissa, S., Garbe, E.
(2006). Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction. Circulation
113: 1950-1957
[Abstract][Full Text]
Wong, P.-S., Asmat, A., Chan, Y.-H., Lee, C.-N.
(2006). A randomized, double-blind, placebo-controlled trial of a COX-2 inhibitor (Rofecoxib) in patients undergoing coronary artery bypass surgery. ICVTS
5: 101-104
[Abstract][Full Text]
Miller, B., Patel, V. A., Sorokin, A.
(2006). Cyclooxygenase-2 Rescues Rat Mesangial Cells from Apoptosis Induced by Adriamycin via Upregulation of Multidrug Resistance Protein 1 (P-Glycoprotein). J. Am. Soc. Nephrol.
17: 977-985
[Abstract][Full Text]
Sooriakumaran, P
(2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J.
82: 242-245
[Abstract][Full Text]
Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., Beasley, R.
(2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.. JRSM
99: 132-140
[Abstract][Full Text]
Blankfield, R. P.
(2006). Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs?. J Am Board Fam Med
19: 178-182
[Abstract][Full Text]
Ridley, D. B., Kramer, J. M., Tilson, H. H., Grabowski, H. G., Schulman, K. A.
(2006). Spending on postapproval drug safety.. Health Aff (Millwood)
25: 429-436
[Abstract][Full Text]
Harris, R. C., Breyer, M. D.
(2006). Update on Cyclooxygenase-2 Inhibitors. CJASN
1: 236-245
[Abstract][Full Text]
Felson, D. T.
(2006). Clinical practice. Osteoarthritis of the knee.. NEJM
354: 841-848
[Full Text]
Honda, T., Segi-Nishida, E., Miyachi, Y., Narumiya, S.
(2006). Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J. Exp. Med.
203: 325-335
[Abstract][Full Text]
Romundstad, L., Breivik, H., Roald, H., Skolleborg, K., Haugen, T., Narum, J., Stubhaug, A.
(2006). Methylprednisolone Reduces Pain, Emesis, and Fatigue After Breast Augmentation Surgery: A Single-Dose, Randomized, Parallel-Group Study with Methylprednisolone 125 mg, Parecoxib 40 mg, and Placebo. Anesth. Analg.
102: 418-425
[Abstract][Full Text]
van den Boom, M., Sarbia, M., von Wnuck Lipinski, K., Mann, P., Meyer-Kirchrath, J., Rauch, B.H., Grabitz, K., Levkau, B., Schror, K., Fischer, J.W.
(2006). Differential Regulation of Hyaluronic Acid Synthase Isoforms in Human Saphenous Vein Smooth Muscle Cells: Possible Implications for Vein Graft Stenosis. Circ. Res.
98: 36-44
[Abstract][Full Text]
Babaev, V. R., Ding, L., Reese, J., Morrow, J. D., Breyer, M. D., Dey, S. K., Fazio, S., Linton, M. F.
(2006). Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E- and Low-Density Lipoprotein Receptor-Null Mice. Circulation
113: 108-117
[Abstract][Full Text]
Bolten, W W
(2006). Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis
65: 7-13
[Abstract][Full Text]
Hall, F. C., Dalbeth, N.
(2005). Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford)
44: 1473-1482
[Abstract][Full Text]
Cui, W., Yu, C.-H., Hu, K.-Q.
(2005). In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells. Clin. Cancer Res.
11: 8213-8221
[Abstract][Full Text]
Chang, T.-C., Huang, C.-J., Tam, K., Chen, S.-F., Tan, K. T., Tsai, M.-S., Lin, T.-N., Shyue, S.-K.
(2005). Stabilization of Hypoxia-inducible Factor-1{alpha} by Prostacyclin under Prolonged Hypoxia via Reducing Reactive Oxygen Species Level in Endothelial Cells. J. Biol. Chem.
280: 36567-36574
[Abstract][Full Text]
Fosslien, E.
(2005). Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs. Annals of Clinical & Laboratory Science
35: 347-385
[Abstract][Full Text]
Csiki, I., Morrow, J. D., Sandler, A., Shyr, Y., Oates, J., Williams, M. K., Dang, T., Carbone, D. P., Johnson, D. H.
(2005). Targeting Cyclooxygenase-2 in Recurrent Non-Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clin. Cancer Res.
11: 6634-6640
[Abstract][Full Text]
Genuis, S. J.
(2005). The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?. J Am Board Fam Med
18: 419-425
[Abstract][Full Text]
Choe, M. S., Zhang, X., Shin, H. J. C., Shin, D. M., Chen, Z.
(2005). Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics
4: 1448-1455
[Abstract][Full Text]
Cipollone, F., Fazia, M. L., Iezzi, A., Cuccurullo, C., De Cesare, D., Ucchino, S., Spigonardo, F., Marchetti, A., Buttitta, F., Paloscia, L., Mascellanti, M., Cuccurullo, F., Mezzetti, A.
(2005). Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in Human. Arterioscler. Thromb. Vasc. Bio.
25: 1925-1931
[Abstract][Full Text]
Pratico, D., Dogne, J.-M.
(2005). Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine. Circulation
112: 1073-1079
[Full Text]
Rigas, B., Kashfi, K.
(2005). Cancer Prevention: A New Era beyond Cyclooxygenase-2. J. Pharmacol. Exp. Ther.
314: 1-8
[Abstract][Full Text]
Gottlieb, S.
(2005). Opening Pandora's Pillbox: Using Modern Information Tools To Improve Drug Safety. Health Aff (Millwood)
24: 938-948
[Abstract][Full Text]
Konstantinopoulos, P. A., Lehmann, D. F.
(2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. J Clin Pharmacol
45: 742-750
[Abstract][Full Text]
Jones, S C.
(2005). Relative Thromboembolic Risks Associated with COX-2 Inhibitors. The Annals of Pharmacotherapy
39: 1249-1259
[Abstract][Full Text]
Rudic, R. D., Brinster, D., Cheng, Y., Fries, S., Song, W.-L., Austin, S., Coffman, T. M., FitzGerald, G. A.
(2005). COX-2-Derived Prostacyclin Modulates Vascular Remodeling. Circ. Res.
96: 1240-1247
[Abstract][Full Text]
Hudson, M., Richard, H., Pilote, L.
(2005). Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ
330: 1370-
[Abstract][Full Text]
Virchow, J. C.
(2005). Fluticasone Reduces CRP in COPD. Am. J. Respir. Crit. Care Med.
171: 1191-1191
[Full Text]
Winters, M. E., Mehta, A. I., Petricoin, E. F. III, Kohn, E. C., Liotta, L. A.
(2005). Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis. Cancer Res.
65: 3853-3860
[Abstract][Full Text]
Montine, T. J., Morrow, J. D.
(2005). Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. Am. J. Pathol.
166: 1283-1289
[Abstract][Full Text]
Fredy, J., Diggins, D. A Jr, Morrill, G. B
(2005). Blood Pressure in Native Americans Switched from Celecoxib to Rofecoxib. The Annals of Pharmacotherapy
39: 797-802
[Abstract][Full Text]
Juhaszova, M., Rabuel, C., Zorov, D. B., Lakatta, E. G., Sollott, S. J.
(2005). Protection in the aged heart: preventing the heart-break of old age?. Cardiovasc Res
66: 233-244
[Abstract][Full Text]
Bernatsky, S., Hudson, M., Suissa, S.
(2005). Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford)
44: 677-680
[Abstract][Full Text]
Bennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., Taubert, K. A.
(2005). The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association. Circulation
111: 1713-1716
[Full Text]
Schror, K., Mehta, P., Mehta, J. L.
(2005). Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors. J CARDIOVASC PHARMACOL THER
10: 95-101
[Abstract]
Wu, K. K., Liou, J.-Y., Cieslik, K.
(2005). Transcriptional Control of COX-2 via C/EBP{beta}. Arterioscler. Thromb. Vasc. Bio.
25: 679-685
[Abstract][Full Text]
Solomon, S. D., McMurray, J. J.V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., Bertagnolli, M., the Adenoma Prevention with Celecoxib (APC) Study,
(2005). Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. NEJM
352: 1071-1080
[Abstract][Full Text]
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., Verburg, K. M.
(2005). Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. NEJM
352: 1081-1091
[Abstract][Full Text]
Alberts, D. S., Potter, J. D., Martinez, M. E., Hess, L. M., Stopeck, A., Lance, P.
(2005). What Happened to the Coxibs on the Way to the Cardiologist?. Cancer Epidemiol. Biomarkers Prev.
14: 555-556
[Full Text]
Bhattacharyya, T., Smith, R. M.
(2005). Cardiovascular Risks of Coxibs: The Orthopaedic Perspective. JBJS
87: 245-246
[Full Text]
Pini, B., Grosser, T., Lawson, J. A., Price, T. S., Pack, M. A., FitzGerald, G. A.
(2005). Prostaglandin E Synthases in Zebrafish. Arterioscler. Thromb. Vasc. Bio.
25: 315-320
[Abstract][Full Text]
Iadecola, C., Gorelick, P. B.
(2005). The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets. Stroke
36: 182-185
[Full Text]
Chang, I. J., Harris, R. C.
(2005). Are All COX-2 Inhibitors Created Equal?. Hypertension
45: 178-180
[Full Text]
Roden, D. M.
(2005). An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation
111: 246-248
[Full Text]
Egan, K. M., Wang, M., Lucitt, M. B., Zukas, A. M., Pure, E., Lawson, J. A., FitzGerald, G. A.
(2005). Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism. Circulation
111: 334-342
[Abstract][Full Text]
Rabausch, K., Bretschneider, E., Sarbia, M., Meyer-Kirchrath, J., Censarek, P., Pape, R., Fischer, J. W., Schror, K., Weber, A.-A.
(2005). Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins. Circ. Res.
96: e1-e6
[Abstract][Full Text]
Previous
